MSN Labs Disrupts Diabetes Care with SEMABEST: India’s First Fully Integrated Semaglutide Follows Patent Expiry

From API to Pen: MSN Laboratories Challenges Global Giants with Integrated Launch of SEMABEST

HYDERABAD – In a move set to redefine the landscape of metabolic care in India, MSN Laboratories has officially launched SEMABEST, the nation’s first vertically integrated semaglutide therapy. Following the recent patent expiry, the CDSCO-approved GLP-1 receptor agonist is hitting the market at a price point nearly 50% lower than the innovator drug, aiming to bridge the massive gap in affordability for India’s 90 million diabetics.

Vertical Integration: The MSN Edge

While the market has seen a flurry of new entrants since late March 2026, MSN Laboratories is positioning SEMABEST as the gold standard for supply chain reliability. Unlike competitors who may rely on external sourcing, MSN’s offering is characterized by:

In-house USDMF-grade API: Ensuring high-purity peptide synthesis.
Domestic Device Manufacturing: The pre-filled subcutaneous pen is manufactured in India under global regulatory standards.
Scalable Infrastructure: Leveraging 25 manufacturing facilities to ensure consistent market supply.

In a move set to redefine the landscape of metabolic care in India, @MSNLabs has officially launched SEMABEST, the nation’s first vertically integrated semaglutide therapy. #SEMABEST #MSNLabs #DiabetesCare https://t.co/0Wk20710tc pic.twitter.com/OF101TXIbJ

— Pharmaleaders (@pharmaleader) April 15, 2026

Clinical Validation & Safety

The clinical efficacy of SEMABEST was highlighted by Dr. Kamini Desai, Head of Medical Affairs at MSN Laboratories, who noted that Phase III trials confirmed the drug’s bioequivalence to the reference innovator.

“The data demonstrates comparable reductions in HbA1c levels, alongside consistent outcomes in fasting plasma glucose (FPG) and weight loss. SEMABEST offers a reliable safety profile that matches the global benchmark,” Dr. Desai stated.

Executive Perspective

Dr. MSN Reddy, Founder & CMD, emphasized the company’s mission to tackle the “silent epidemic” of diabetes in India. “The launch of SEMABEST is a defining step in making next-generation metabolic therapies accessible. As diabetes burdens rise, our focus remains on high-quality, indigenous innovation.”

Bharat Reddy, Executive Director, underscored the company’s decade-long expertise in peptides, dating back to their first USDMF filing in 2016. “With 12 peptide USDMFs and 6 US ANDAs for peptide formulations already in our portfolio, MSN is uniquely positioned to handle the complexities of large-scale peptide production,” he added.

Strategic Context: Why This Matters

India remains the “Diabetes Capital of the World,” where complications like cardiovascular disease and renal failure place an immense strain on the healthcare system. By slashing the cost of Semaglutide—a molecule widely recognized for its dual benefit in glucose control and weight management—MSN is not just launching a product; they are democratizing a therapeutic class that was previously cost-prohibitive for the average Indian patient.

MSN Laboratories: At a Glance

Established: 2003
Global Reach: Serving 50M+ patients across 100+ countries.
R&D Powerhouse: 1,000+ patents filed; 560+ USDMFs (a global leader).
Portfolio: 550+ APIs and 400+ finished dosage forms across 35 therapeutic areas.